Literature DB >> 35265702

Reply: External validation of the OPALS prediction model for in-hospital mortality in patients with acute decompensated pulmonary hypertension.

Robin Condliffe1,2, Kris Bauchmuller3, Jennifer Southern3, David G Kiely1,2, Gary H Mills3,4.   

Abstract

The OPALS score appears to be a promising PH-specific tool for predicting outcomes in medically decompensated patients https://bit.ly/3rTxzbr.
Copyright ©The authors 2022.

Entities:  

Year:  2022        PMID: 35265702      PMCID: PMC8899494          DOI: 10.1183/23120541.00066-2022

Source DB:  PubMed          Journal:  ERJ Open Res        ISSN: 2312-0541


From the authors: We were very interested to read the correspondence by M.V.F. Garcia and colleagues [1]. They have assessed our previously proposed predictive score for outcomes in medically decompensated pulmonary hypertension (PH) patients: the OPALS score (oxygen (oxygen saturation measured by pulse oximetry/inspiratory oxygen fraction ratio ⩽185), platelets ⩽196×109 L−1, age ⩾37.5 years, lactate ⩾2.45 mmol·L−1 and sodium ⩽130.5 mmol·L−1) in 74 PH patients. Discriminatory power was very similar to that observed in our derivation cohort (c-statistic of 0.77 versus 0.78) [2]. Furthermore, there was exceedingly high calibration between predicted and observed mortality in their validation cohort (R2=0.97). The OPALS score therefore appears to be a promising PH-specific tool for predicting outcomes in medically decompensated patients. Further work is, however, needed to compare its accuracy and utility compared with other intensive care unit (ICU) scoring systems and PH risk-stratification tools, and to assess its responsiveness to changing clinical severity during patients’ ICU admission.
  1 in total

1.  Critical care outcomes in patients with pre-existing pulmonary hypertension: insights from the ASPIRE registry.

Authors:  Kris Bauchmuller; Robin Condliffe; Jennifer Southern; Catherine Billings; Athanasios Charalampopoulos; Charlie A Elliot; Abdul Hameed; David G Kiely; Ian Sabroe; A A Roger Thompson; Ajay Raithatha; Gary H Mills
Journal:  ERJ Open Res       Date:  2021-04-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.